During the corresponding time, Organogenesis Holdings Inc saw a revenue deteriorated by -56.68 % year on year, sequentially revenue grew by 17.53 %. While revenue at the Organogenesis Holdings Inc 's corporate clients
Organogenesis Holdings Inc's Comment on Sales, Marketing and Customers
The company provides customer support to various healthcare customers, including hospitals, wound care centers, government facilities, ambulatory surgery centers (ASCs), and physician offices. It serves the Advanced Wound Care market with products for chronic and acute wounds, such as Apligraf, Dermagraft, PuraPly AM, PuraPly XT, CYGNUS Dual, CYGNUS Matrix, VIA Matrix, Affinity, Novachor, NuShield, and SimpliMax. In the Surgical & Sports Medicine market, the company offers products including NuShield, Cygnus Matrix, PuraForce, Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for surgical wounds and tendon and ligament injuries. The company is influenced by Medicare Part A/B Administrative Contractors' local coverage determinations (LCDs) and Centers for Medicare & Medicaid Services (CMS) regulations concerning skin substitute grafts and cellular and tissue-based products for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
In a landmark announcement for the field of regenerative medicine, Organogenesis Holdings Inc. (Nasdaq: ORGO), renowned for its pioneering work in advanced wound care and surgical solutions, has reported a favorable outcome from the interim analysis of its second Phase 3 clinical trial of ReNu. This innovative cryopreserved amniotic suspension allograft (ASA) aims to manage symptoms associated with knee osteoarthritis (OA), a condition affecting millions and significantly impacting quality of life.The study, which is pivotal in understanding the efficacy and safety of ReNu, involved a robust randomized control trial design, emphasizing the commitment of Organogenesis to rigorous scientific protocols. The pos...
CANTON, Mass., Aug. 8, 2024 - Organogenesis Holdings Inc. (Nasdaq: ORGO), a frontrunner in regenerative medicine dedicated to the advanced wound care and surgical sports medicine markets, has announced a significant development update on its ReNu® program. ReNu®, a cryopreserved amniotic suspension allograft (ASA), is designed to manage the symptoms associated with knee osteoarthritis (OA), an ailment affecting millions worldwide. Organogenesis continuously strives to push the boundaries of regenerative medicine, and ReNu® exemplifies this commitment. The program aims to address the urgent needs of patients suffering from knee OA, a prevalent condition that results in pain, swelling, and decreased mobilit...
Organogenesis Holdings Inc’s Comment on Sales, Marketing and Customers
The company provides customer support to various healthcare customers, including hospitals, wound care centers, government facilities, ambulatory surgery centers (ASCs), and physician offices. It serves the Advanced Wound Care market with products for chronic and acute wounds, such as Apligraf, Dermagraft, PuraPly AM, PuraPly XT, CYGNUS Dual, CYGNUS Matrix, VIA Matrix, Affinity, Novachor, NuShield, and SimpliMax. In the Surgical & Sports Medicine market, the company offers products including NuShield, Cygnus Matrix, PuraForce, Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for surgical wounds and tendon and ligament injuries. The company is influenced by Medicare Part A/B Administrative Contractors' local coverage determinations (LCDs) and Centers for Medicare & Medicaid Services (CMS) regulations concerning skin substitute grafts and cellular and tissue-based products for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
Sources:
Organogenesis Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Organogenesis Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Organogenesis Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
180.68 %